In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

[Q]: Zika virus (ZIKV) infection can be the cause of congenital malformations, including microcephaly in infants and can cause other disorders such as Guillain-Barre syndrome, meningoencephalitis, and myelitis, which can also occur in some infected adults. However, at this time, there is no drug approved to treat ZIKV infection. Drug repurposing is the promptest way to obtain an effective drug during a global public health emergency such as the spread of Zika virus. In this study, we report a US Food and Drug Admistration-approved drug that is safe for pediatric use. Nitazoxanide and its bioactive metabolite, tizoxanide, have anti-ZIKV potential in vitro, and we identified that they exerts antiviral effect possibly by targeting the viral postattachment step.
[A]: Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika

[Q]: Bacille Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis currently used as a vaccine against tuberculosis. Global distribution and propagation of BCG has contributed to the in vitro evolution of the vaccine strain and is thought to partially account for the different outcomes of BCG vaccine trials. Previous efforts by several molecular techniques effectively identified large sequence polymorphisms among BCG daughter strains, but lacked the resolution to identify smaller changes. In this study, we have used a NimbleGen tiling array for whole genome comparison of 13 BCG strains. Using this approach, in tandem with DNA resequencing, we have identified six novel large sequence polymorphisms including four deletions and two duplications in specific BCG strains. Moreover, we have uncovered various polymorphisms in the phoP-phoR locus. Importantly, these polymorphisms affect genes encoding established virulence factors including cell wall complex lipids, ESX secretion systems, and the PhoP-PhoR two-component system. Our study demonstrates that major virulence factors are different among BCG strains, which provide molecular mechanisms for important vaccine phenotypes including adverse effect profile, tuberculin reactivity and protective efficacy. These findings have important implications for the development of a new generation of vaccines.
[A]: BMC Genomics Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

[Q]: A mong the infl ammatory processes triggering COPD exacerbations, respiratory tract viral infections are prime suspects. Although fi rst localized in the upper-respiratory tract (URT), these infections could trigger a cascade of infl ammatory events 1,2 that lead to clinically signifi cant exacerbations. Current guidelines recommend the administration of antibiotics based mainly on clinical criteria, 1 leading inevitably to an overuse of antibiotics, which is estimated to occur in approximately 55% of all acute exacerbations of COPD (AECOPD). 3 The participation of viral infections in AECOPD has been confi rmed in many studies. 4-7 The most recent reports using polymerase chain reaction (PCR)-based methods led to a positive detection of viral nucleic acids in 30% to 60% of AECOPD cases. 5,8-12 However, the role of recently identifi ed viruses, such as coronavirus NL63 and HKU1 and human bocavirus as well as the new human rhinoviruses C, which are reported as the most frequent ones circulating in the community, 13, 14 has not yet been fully established. Biomarkers such as procalcitonin (PCT), when elevated, have been proposed as surrogate markers of bacterial disease and, when within normal values, often are considered in clinical practice as the signature of a viral infection. Although PCT has been studied Background: Respiratory viruses frequently are recovered in the upper-respiratory tract during acute exacerbations of COPD (AECOPD), but their role as contributing pathogens remains unclear. The usefulness of procalcitonin and C-reactive protein as indicators of the presence or absence of viral infection in this setting also needs to be evaluated. Methods: The study was of a prospective cohort of patients with COPD admitted to the ED for AECOPD. Reverse transcriptase-polymerase chain reaction (RT-PCR) for 14 respiratory viruses was performed on nasopharyngeal swabs collected at admission and after recovery in stable condition. Conclusions: Prevalence of upper-respiratory viral infection, as detected from nasopharyngeal swab by RT-PCR, is high in AECOPD and low after clinical recovery, suggesting that AECOPD frequently are triggered by viral infections initiated in the upper-respiratory tract. In our study, serum procalcitonin and C-reactive protein did not discriminate virus-associated exacerbations from others. Trial registration: clinicaltrials.gov; Identifi er: NCT00448604. Abbreviations: AECOPD 5 acute exacerbations of COPD; CRP 5 C-reactive protein; OR 5 odds ratio; PCR 5 polymerase chain reaction; PCT 5 procalcitonin; PEF 5 peak expiratory fl ow; RSV 5 respiratory syncytial virus; RT-PCR 5 reverse transcriptase-polymerase chain reaction; URT 5 upper-respiratory tract
[A]:
Upper-Respiratory Viral Infection, Biomarkers, and COPD Exacerbations